Hydrocodone


Description

Narcotic analgesic related to codeine, but more potent and more addicting by weight. It is used also as cough suppressant.

Read more

Pharmacology

Indication

For relief of moderate to moderately severe pain. Also used for the symptomatic relief of nonproduct... Read more

Pharmacodynamic

Hydrocodone, a semisynthetic opiate agonist and hydrogenated ketone derivative, is similar to other... Read more

Mechanismofaction

Hydrocodone acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous... Read more

Absorption

Well absorbed from the gastrointestinal tract.

Proteinbinding

As most agents in the 5-ring morphinan group of semi-synthetic opioids bind plasma protein to a simi... Read more

Volumeofdistribution

Information currently not available.

Clearance

Information currently not available.

Halflife

1.25-3 hours

Routeofelimination

Information currently not available.

Toxicity

Symptoms of overdose include respiratory depression (a decrease in respiratory rate and/or tidal vol... Read more


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Headache US
  • Kind: experimental
    • Percent: 27%
  • Clinical Trial
    Somnolence US
  • Kind: experimental
    • Percent: 22%
  • Clinical Trial
    Constipation US
  • Kind: experimental
    • Percent: 22%
  • Clinical Trial
    Nausea US
  • Kind: experimental
    • Percent: 21%
  • Clinical Trial
    Dizziness US
  • Kind: experimental
    • Percent: 14%
  • Clinical Trial
    Dyspepsia US
  • Kind: experimental
    • Percent: 12%
  • Clinical Trial
    Constipation US
  • Kind: experimental
    • Percent: 8-11%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Neck Pain US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Pain in extremity US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Osteoarthritis US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Lethargy US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Migraine US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Anxiety US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Paresthesia US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Depression US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Insomnia US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Dyspnea US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Cough US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Hyperhidrosis US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Night Sweats US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Rash US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Hot flush US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Abdominal Pain US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Andominal discomfort US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Pain US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Non-Cardiac Chest Pain US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Gastroesophageal Reflux Disease US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Contusion US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Pyrexia US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Peripheral Edema US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Foot fracture US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Fall US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Muscle Strain US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Joint injury US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Joint sprain US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Increased blood cholesterol US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Increased gamma-glutamyltransferase US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Skin laceration US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Hypokalemia US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Dehydration US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Myalgia US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Arthralgia US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Musculoskeletal Pain US
  • Kind: experimental
    • Percent: ≥1%-<10%
  • Clinical Trial
    Nausea US
  • Kind: experimental
    • Percent: 7-10%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Asthenia US
  • Kind: experimental
    • Percent: 3-9%
  • Clinical Trial
    Abdominal Pain US
  • Kind: experimental
    • Percent: 3-9%
  • Clinical Trial
    Insomnia US
  • Kind: experimental
    • Percent: 3-9%
  • Clinical Trial
    Infection US
  • Kind: experimental
    • Percent: 3-9%
  • Clinical Trial
    Anxiety US
  • Kind: experimental
    • Percent: 3-9%
  • Clinical Trial
    Sweating US
  • Kind: experimental
    • Percent: 3-9%
  • Clinical Trial

    Contraindications

    Information currently not available.

    Food Interactions

    • Avoid alcohol.
    • Take with food.
    • To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables).

    Interactions

    Type in a drug name to check for interaction with Hydrocodone

    The metabolism of (R)-warfarin can be decreased when combined with Hydrocodone.
    The metabolism of (S)-Warfarin can be decreased when combined with Hydrocodone.
    The risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with 2,5-Dimethoxy-4-ethylamphetamine.
    The risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
    The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Hydrocodone.
    The risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with 4-Bromo-2,5-dimethoxyamphetamine.
    4-Bromo-2,5-dimethoxyphenethylamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
    The metabolism of 4-hydroxycoumarin can be decreased when combined with Hydrocodone.
    4-Methoxyamphetamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
    The metabolism of 5-androstenedione can be decreased when combined with Hydrocodone.
    The risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with 5-methoxy-N,N-dimethyltryptamine.
    The metabolism of Hydrocodone can be decreased when combined with 6-Deoxyerythronolide B.
    The metabolism of 6-O-benzylguanine can be decreased when combined with Hydrocodone.
    The metabolism of Hydrocodone can be decreased when combined with 7-ethyl-10-hydroxycamptothecin.
    7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
    7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.
    The metabolism of 9-aminocamptothecin can be decreased when combined with Hydrocodone.
    The metabolism of Hydrocodone can be increased when combined with Abatacept.
    The metabolism of Abemaciclib can be decreased when combined with Hydrocodone.
    The metabolism of Hydrocodone can be decreased when combined with Abiraterone.

    References

      Information currently not available.

    Recent Questions